Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
Sundar Jagannath, M.D., Chief of the Multiple Myeloma Program, Bone Marrowand Blood Stem Cell Transplantation at St. Vincent's Comprehensive CancerCenter in New York will present initial results from Proteolix's Phase 2 studyof carfilzomib for the treatment of patients with relapsed and refractorymultiple myeloma during the Novel Therapies for Myeloma and Related Disorderssession at 7:00 a.m. on Tuesday, December 9, 2008. This ongoing Phase 2 trialis an open-label multi-center study of single-agent carfilzomib in patientswho have previously failed at least two prior treatments, containingbortezomib and either lenalidomide or thalidomide, and are refractory to theirlast treatment. Data from a second ongoing Phase 2 clinical trial ofsingle-agent carfilzomib in relapsed multiple myeloma patients (stratified byprior therapy with bortezomib) will be presented immediately thereafter at7:15 a.m. by Ravi Vij, M.D., Associate Professor of Medicine, Division ofOncology, Section of Bone Marrow Transplantation, Washington University Schoolof Medicine.
In addition to the oral presentations, the company will have severalposter presentations highlighting the results of preclinical studies thatfurther characterize the mechanism and safety profile of carfilzomib.Proteolix will also have a poster presentation on the preclinical pharmacologyand characterization of its oral proteasome inhibitor known as PR-047.
A complete list of the company's oral and poster presentations at the ASHmeeting follows:
Proteolix, Inc. is a privately-held biopharmaceutical company,headquartered in South San Francisco, dedicated to discovering, developing andcommercializing novel therapeutics that target protein degradation pathwaysfor cancer and autoimmune diseases. Proteolix's lead product, carfilzomib(PR-171), the first in a new class of highly specific proteasome inhibitors,is currently in multiple Phase 2 clinical studies to evaluate its safety andefficacy in hematologic and solid tumor malignancies. Proteolix is alsodeveloping a pipeline of novel proteasome inhibitors, including an oralproteasome inhibitor and a selective immunoproteasome inhibitor. Foradditional information on Proteolix, please visit http://www.proteolix.com.Oral Presentations -- Tuesday, December 9, 2008 Session: Novel Therapies for Myeloma and Related Disorders -- 7:00 a.m. PST: Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM) (Abstract #864) -- 7:15 a.m. PST: Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM) (Abstract #865) Location: Moscone Center, Gateway Ballroom 103-South Poster Presentations Sunday, December 7, 2008, 6:00 p.m. -- 8:00 p.m. PST Session: Molecular Pharmacology, Drug Resistance Poster II -- Non-Proteasomal Targets of Proteasome Inhibitors Bortezomib and Carfilzomib (Abstract #2657) Session: Myeloma -- Pathophysiology and Preclinical Studies Excluding Therapy Poster II -- The Selective Proteasome Inhibitor Carfilzomib is Well Tolerated in Experimental Animals with Dose Intensive Administration (Abstract #2765) Location: Moscone Center Hall A Monday, December 8, 2008, 5:30 p.m. -- 7:30 p.m. PST Session: Myeloma -- Pathophysiology and Preclinical Studies Excluding Therapy Poster III -- Induction of Sustained Early G1 Arrest by Selective Inhibition of CDK4 and CDK6 Primes Myeloma Cells for Synergistic Killing by Proteasome Inhibitors Carfilzomib and PR-047 (Abstract #3670) -- Preclinical Pharmacology and in vitro Characterization of PR-047, An Oral Inhibitor of the 20S Proteasome (Abstract #3671) Location: Moscone Center Hall A
SOURCE Proteolix, Inc.
You May Also Like